证券代码：300363 证券简称：博腾股份 博腾股份投资者关系活动记录表 编号：00220220128 | --- | --- | --- | --- | --- | |-----------------------|-----------------------------------|---------------------------------------------------|----------------------------------------|------------------------------------------------------| | 投资者关系活 \n动类别 | □媒体采访 \n□现场参观 \n□其他 | ■特定对象调研 □分析师会议 \n□新闻发布会 □路演活动 | □业绩说明会 \n□电话通讯 | | | | 德邦证券： | 陈铁林 | | | | | 凯石基金： | 吴蔽野 | | | | 参与单位名称 | 凯石基金： | 唐楚彦 | | | | 及人员姓名 | 前海开源基金：黄智然 | | | | | | 华富基金： | 张瑞 | | | | 时间 ...

证券代码：300363 证券简称：博腾股份 博腾股份投资者关系活动记录表 编号：00120220105 | --- | --- | --- | --- | |-------------------------|----------------------------|------------------------------------------|------------------------------------------------------| | | | | | | | | ■特定对象调研 □分析师会议 | | | | □媒体采访 | □业绩说明会 | | | 投资者关系活 | | □新闻发布会 □路演活动 | | | 动类别 | □现场参观 | □电话通讯 | | | | □其他 | | | | 参与单位名称 及人员姓名 | 新华基金：谷航 | | | | 时间 | 2022 年 1 月 | | | | | | | | | | 地点 公司重庆水土研发中心 | | | | 上市公司接待 | 陈靓 投资者关系副经理 | | | | 人员姓名 | 周泉铭 投资者关系主管 | | | | | 公司 ...

证券代码：300363 证券简称：博腾股份 博腾股份投资者关系活动记录表 编号：00520220516 | --- | --- | --- | --- | |-------------------------|----------------------------------------|-----------------------|--------------------------------------------------------| | | | | | | | ■特定对象调研 □分析师会议 | | | | | □媒体采访 | | □业绩说明会 | | 投资者关系活 动类别 | □新闻发布会 □路演活动 | | | | | □现场参观 | □电话通讯 | | | | □其他 | | | | 参与单位名称 及人员姓名 | 深圳九腾资产管理有限公司 | | | | 时间 | 2022 年 5 月 16 日 | | | | | 地点 公司重庆水土研发中心 | | | | | 汪星星 证券事务代表 | | | | 上市公司接待 | 陈靓 投资者关系副经理 | | | | 人员姓名 | 董事会办公室 I ...

证券代码：300363 证券简称：博腾股份 博腾股份投资者关系活动记录表 编号：00420220429 | --- | --- | --- | |------------------|-------------------------------------|-----------------------------------------------------------------------------------| | | | | | | □特定对象调研 □分析师会议 | | | | □媒体采访 | ■业绩说明会 | | 投资者关系活动类 | □新闻发布会 □路演活动 | | | 别 | □现场参观 | □电话通讯 | | | □其他 | | | 参与单位名称及人 | 线上投资者 | | | 员姓名 | | | | 时间 | 2022 年 4 月 29 日 | | | | 地点 "进门财经"及"路演中"电话会议 | | | 上市公司接待人员 | 居年丰 董事长、总经理 | | | | 陈晖 副总经理、财务负责人 | | | 姓名 | | | | | 皮薇 副总经理、董事会秘书 | | | | 财务表 ...

证券代码：300363 证券简称：博腾股份 博腾股份投资者关系活动记录表 编号：00720220630 | --- | --- | --- | |---------------------|-----------------------------------|--------------------------------------------------------| | | | | | | ■特定对象调研 □分析师会议 | | | | □媒体采访 | □业绩说明会 | | 投资者关系活 动类别 | □新闻发布会 □路演活动 | | | | ■现场参观 | □电话通讯 | | | □其他 | | | 参与单位名称 | | 安信证券私人财富中心、重庆德睿恒丰资产管理有限公司、 | | 及人员姓名 | | 重庆诺鼎资产管理有限公司以及个人投资者共计 23 人 | | 时间 | 2022 年 6 月 30 日 | | | | 地点 公司重庆水土研发中心 | | | 上市公司接待 | 皮薇 副总经理、董事会秘书 | | | 人员姓名 | 董事会办公室 IR 团队 | | | | 一、投资者参观公司水土研发中心 ...

证券代码：300363 证券简称：博腾股份 博腾股份投资者关系活动记录表 编号：00620220601 | --- | --- | --- | --- | |---------------------|------------------------------------------|-----------------|-------------------------------------------------------| | | | | | | | ■特定对象调研 □分析师会议 | | | | | □媒体采访 | □业绩说明会 | | | 投资者关系活 动类别 | □新闻发布会 □路演活动 | | | | | □现场参观 | □电话通讯 | | | | □其他 | | | | 参与单位名称 | 民生证券 许睿 | | | | 及人员姓名 | 融通基金 陈顺 | | | | 时间 | 2022 年 6 月 1 日 | | | | 地点 | 公司重庆水土研发中心 | | | | 上市公司接待 | 皮薇 副总经理、董事会秘书 | | | | | 陈靓 投资者关系副经理 | | | | 人员姓名 | 董事 ...

证券代码：300363 证券简称：博腾股份 博腾股份投资者关系活动记录表 编号：00920221026 | --- | --- | --- | |-----------------------------|-------------------------------------------------|--------------------------------------------------------------| | | | | | | | | | | □特定对象调研 □分析师会议 | | | 投资者关系活动类 | □媒体采访 | ■业绩说明会 | | 别 | □新闻发布会 □路演活动 □现场参观 | □电话通讯 | | | | | | | □其他 海通证券：余文心、周航 | | | | | | | 参与单位名称及人 | 长江证券：郭心驰 申万宏源证券：王道 | | | 员姓名 | 天风证券：贺晓晗 | | | | 线上投资者约 160 人 | | | | | | | 时间 | 2022 年 10 月 26 日 | | | | | | | | 地点 "进门财经"及"路演中"线上会议 | | | ...

| --- | --- | --- | --- | --- | |----------------------------------------------|-------|-------|-------|------------------------------| | | | | | | | | | | | | | | | | | | | 博腾股份（ 300363) 2022 年第三季度业绩说明会 | | | | | | | | | | | | | | | | | | 2022 年 10 月 26 日 | | | | | | 让好药更早惠及大众 | | | | | | | | | | | | www.porton.cn | | | | Porton Pharma Solutions Ltd. | | | | | | | | --- | --- | |----------------------------------------------|-------| | | | | | | | 关于前瞻性陈述（ Forward-Looking Statements) | | | | | | | | 2022年前 ...

Financial Performance - The company's revenue for Q3 2022 reached ¥1,303,577,566.55, representing a 68.42% increase year-over-year[6]. - Net profit attributable to shareholders was ¥365,447,482.53, up 150.08% compared to the same period last year[6]. - The net profit after deducting non-recurring gains and losses was ¥365,491,661.64, reflecting a 141.15% increase year-over-year[6]. - The basic earnings per share (EPS) was ¥0.67, an increase of 148.15% from the previous year[6]. - Total revenue for the first nine months of 2022 reached CNY 5,217,592,886.95, a 157.05% increase compared to CNY 2,029,816,801.54 in the same period of 2021[16]. - Net profit for the first nine months surged to CNY 2,992,451,126.36, a 96.91% increase from CNY 1,519,689,348.80 in the previous year[16]. - The overall gross margin for the reporting period was 52.56%, an increase of 8.85 percentage points year-on-year[29]. - Operating profit for the period was ¥1,749,356,581.71, up from ¥389,327,250.60, reflecting a growth of 348.5% year-over-year[65]. - Net profit attributable to shareholders of the parent company was ¥1,577,785,680.52, compared to ¥360,700,820.85 in the previous year, marking an increase of 338.5%[65]. Assets and Liabilities - Total assets as of September 30, 2022, amounted to ¥10,147,132,892.55, a 54.63% increase from the end of the previous year[6]. - Total liabilities increased to ¥4,131,497,307.22 from ¥2,375,948,241.39, representing a growth of 73.8%[65]. - The company’s total assets reached ¥10,147,132,892.55, compared to ¥6,562,035,209.95, indicating a growth of 54.5%[65]. - The company’s inventory increased to RMB 1,078.96 million as of September 30, 2022, compared to RMB 757.39 million at the beginning of the year, reflecting a growth of 42.5%[58]. - The company’s accounts receivable increased to RMB 1,249.62 million as of September 30, 2022, compared to RMB 1,035.07 million at the beginning of the year, showing an increase of 20.7%[58]. Cash Flow - The company's cash flow from operating activities for the year-to-date reached ¥2,303,661,711.51, a significant increase of 819.16%[6]. - The net cash flow from operating activities for the current period is CNY 2,303,661,711.51, a significant increase from CNY 250,627,959.49 in the previous period[71]. - Cash inflow from operating activities totaled CNY 4,528,728,396.70, compared to CNY 1,989,701,745.37 in the prior period, reflecting a growth of approximately 127.4%[71]. - Cash flow from financing activities showed a significant increase, with cash received from borrowings reaching CNY 1,091,827,163.00, up 732.67% from CNY 131,124,079.81[16]. - The ending balance of cash and cash equivalents increased to CNY 2,880,227,808.05 from CNY 1,176,814,356.74, representing a growth of approximately 144.4%[71]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 42,176[19]. - The largest shareholder, Chongqing Liangjiang New Area Industrial Development Group Co., Ltd., holds 14.51% of shares, totaling 78,982,719 shares[19]. - The second-largest shareholder, Ju Nianfeng, owns 10.82% of shares, amounting to 58,890,521 shares, with 44,167,891 shares pledged[19]. - The company has a total of 10 major shareholders, with the top 10 holding a significant portion of the shares[19]. - The report confirms that the top 10 shareholders do not participate in margin financing[19]. Research and Development - The company’s R&D expenses rose to CNY 450,657,966.94, a 101.53% increase from CNY 223,621,085.82, reflecting ongoing investment in technology and product development[16]. - Research and development expenses amounted to ¥450,657,966.94, which is an increase of 101.9% from ¥223,621,085.82 in the same period last year[65]. Investments and Acquisitions - The company acquired 100% equity of Kaihui Pharmaceutical (Shanghai) Co., Ltd., contributing to a 94.14% increase in intangible assets[9]. - The company is expanding its CDMO factory and other projects, leading to a 137.07% increase in construction in progress[9]. - The company is investing 50 million euros to build a small molecule R&D and production base in Slovenia, expected to be operational by September 2024[46]. - The company has approved a B-round financing for its subsidiary, Suzhou Boteng Biopharmaceutical Co., Ltd., amounting to RMB 52 million, with external investors contributing RMB 40 million[54]. Tax and Expenses - The company’s tax expenses surged to CNY 227,580,076.54, a 596.89% increase from CNY 32,656,561.35, driven by higher profitability[16]. - The company paid taxes amounting to CNY 383,809,619.26, significantly higher than CNY 132,106,842.11 in the prior period, indicating an increase of about 189.5%[71].

Company Operations and Workforce - The company operates 16 facilities globally, with a production capacity of 2100m3 for active pharmaceutical ingredients (API) and over 29,000m2 of laboratory space[5][6]. - The workforce includes over 4,700 employees, with a dedicated R&D team of more than 1,400 professionals[7]. - The company has served over 700 global clients and has delivered approximately 2,000 projects, with 93 API products currently in service[8]. Financial Performance - The company's revenue for the reporting period reached ¥3,914,015,320.40, representing a 211.67% increase compared to ¥1,255,818,823.39 in the same period last year[33]. - Net profit attributable to shareholders was ¥1,212,338,197.99, a significant increase of 465.01% from ¥214,568,940.73 in the previous year[33]. - The net profit after deducting non-recurring gains and losses was ¥1,211,451,857.98, reflecting a 501.87% increase compared to ¥201,282,796.53 in the prior year[33]. - The company reported a net cash flow from operating activities of ¥510,025,930.86, which is a 263.31% increase from ¥140,384,093.27 in the same period last year[33]. - Basic earnings per share increased to ¥2.23, up 471.79% from ¥0.39 in the previous year[33]. - Total assets at the end of the reporting period were ¥9,542,949,012.00, a 45.43% increase from ¥6,562,035,209.95 at the end of the previous year[33]. Research and Development - The company aims to enhance its R&D capabilities and expand its market presence in the pharmaceutical industry[38]. - The company has established a comprehensive capability system covering API CDMO, formulation CDMO, and gene cell therapy CDMO, providing end-to-end services for drug development[41]. - The company introduced 70 new customers during the first half of 2022, with a total of 284 customers served, representing a 28% year-on-year growth[53]. - The company’s R&D expenses amounted to 280.54 million yuan, reflecting a year-on-year increase of approximately 109%[72]. Market and Client Engagement - The company has received 1,092 inquiries and introduced 70 new clients during the reporting period[8]. - The total number of customer inquiries exceeded 1,000, marking a 30% year-on-year increase, indicating strong customer demand[58]. - The company is involved in various therapeutic areas, including antiviral, oncology, and rare diseases, with a focus on innovative drug development[2][4]. Social Responsibility and Community Engagement - The company plans to continue its commitment to social responsibility, actively participating in rural revitalization and pandemic response efforts[9]. - The company has introduced the "We Care" initiative to enhance its social welfare brand and community engagement[10][11]. - The company has engaged in social responsibility initiatives, including participation in poverty alleviation and rural revitalization activities, with over 50 volunteers involved in related efforts[143]. Environmental Management - The company has established a robust EHS management system, ensuring sustainable development and compliance with international standards[45]. - The company is focused on continuous improvement in its environmental performance, aiming to reduce overall emissions and enhance treatment processes[117]. - The company has implemented a comprehensive air pollution control strategy, including the use of RTO (Regenerative Thermal Oxidizers) to manage emissions effectively[129]. - The company is actively monitoring and managing its emissions and discharges to ensure sustainable operations and environmental responsibility[121]. Risks and Challenges - The company faces risks related to market demand fluctuations, fixed asset investments, and potential recalls of innovative drugs[14]. - The company experienced foreign exchange losses of RMB -39.77 million, RMB 10.79 million, and RMB 61.93 million over the last two years and the current period, indicating significant volatility in performance due to currency fluctuations[97]. - New business segments collectively reduced the company's net profit by approximately RMB 72.58 million during the reporting period, highlighting the risks associated with new investments[98]. Strategic Initiatives - The company aims to become the most open, innovative, and reliable pharmaceutical service platform globally, providing comprehensive CDMO services[14]. - The company plans to enhance market development efforts and introduce industry-leading talent to mitigate risks associated with new business investments[98]. - The company has implemented three major strategies: marketing transformation, product upgrades, and the development of process chemistry CRO to mitigate risks associated with customer and product concentration[94]. Stock and Shareholder Information - The company approved the 2022 Restricted Stock Incentive Plan, with 570,200 shares granted to 211 participants at a price adjusted to 41.31 CNY per share[109]. - Major shareholders have pledged shares totaling 23,647,475 shares (40.15%), 14,327,475 shares (32.42%), and 8,747,475 shares (20.88%), representing 4.35%, 2.63%, and 1.61% of the company's total shares, respectively[159]. - The company has a total of 81,595,313 shares under various stock incentive plans, with 11,352,708 shares available for future allocation[178]. Financial Health and Investments - The total amount of raised funds is RMB 146,202.76 million, with RMB 1,313.48 million utilized during the reporting period[86]. - The company’s total approved guarantee amount at the end of the reporting period was RMB 82.01 million, with actual guarantees totaling RMB 42.12 million[155]. - The company’s total liabilities reached CNY 3,266,797,756.10, compared to CNY 1,596,645,407.42 in the previous year, marking an increase of about 104%[198].